Literature DB >> 8630949

Prevalence and prognostic significance of tumor-associated tissue eosinophilia in nasopharyngeal carcinoma.

S E Leighton1, J G Teo, S F Leung, A Y Cheung, J C Lee, C A van Hasselt.   

Abstract

BACKGROUND: Tumor-associated tissue eosinophilia (TATE) has been associated with an improved prognosis in a variety of neoplasms.
METHODS: Diagnostic biopsy specimens from 96 patients with nasopharyngeal carcinoma (NPC) were reviewed for the presence of TATE by an observer blinded to the patients' clinical histories. Comparisons between patients with and without TATE with respect to the probabilities of local recurrence, distant metastasis, and survival were performed using the log rank test on Kaplan-Meier product-limit estimates and the Cox proportional hazards model.
RESULTS: The prevalence of TATE in these patients was 32%, and was not significantly associated with local recurrence, distant metastasis, or survival.
CONCLUSIONS: These results are discordant with those of studies in other tumor models, although comparison is hampered by varying definitions of TATE. The differing results may be due to variations in the degree of activation of the eosinophils present in TATE in different tumors.

Entities:  

Mesh:

Year:  1996        PMID: 8630949     DOI: 10.1002/(SICI)1097-0142(19960201)77:3<436::AID-CNCR3>3.0.CO;2-I

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

Review 1.  Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.

Authors:  Zhaleh J Amini-Vaughan; Margarita Martinez-Moczygemba; David P Huston
Journal:  Curr Allergy Asthma Rep       Date:  2012-10       Impact factor: 4.806

2.  Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation.

Authors:  S Ali; J Kaur; K D Patel
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

3.  Tumour-Associated Tissue Eosinophilia in Oral Squamous Cell Carcinoma- A Boon or a Bane?

Authors:  Shweta Yellapurkar; Srikant Natarajan; Karen Boaz; Mohan Baliga; Premalatha Shetty; Nidhi Manaktala; Mukul Prasad; Mahalakshmi Ravi
Journal:  J Clin Diagn Res       Date:  2016-04-01

4.  Primary esophageal sclerosing mucoepidermoid carcinoma with "tissue eosinophilia".

Authors:  Suman Mewa Kinoo; Kapil Maharaj; Bhugwan Singh; Michelle Govender; Pratistadevi Kanaye Ramdial
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

5.  Significance of neo-angiogenesis and immuno-surveillance cells in squamous cell carcinoma of the tongue.

Authors:  Juma O Alkhabuli
Journal:  Libyan J Med       Date:  2007-03-01       Impact factor: 1.657

Review 6.  Immune suppression in head and neck cancers: a review.

Authors:  Anaëlle Duray; Stéphanie Demoulin; Pascale Hubert; Philippe Delvenne; Sven Saussez
Journal:  Clin Dev Immunol       Date:  2011-03-10

7.  Influence of pathological tumour variables on long-term survival in resectable gastric cancer.

Authors:  A Cuschieri; I C Talbot; S Weeden
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

8.  Eosinophils and oral squamous cell carcinoma: a short review.

Authors:  C P Martinelli-Kläy; B R R N Mendis; T Lombardi
Journal:  J Oncol       Date:  2009-12-16       Impact factor: 4.375

Review 9.  Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development.

Authors:  Valérie Gouon-Evans; Elaine Y Lin; Jeffrey W Pollard
Journal:  Breast Cancer Res       Date:  2002-06-25       Impact factor: 6.466

10.  Assessment of tissue eosinophilia as a prognosticator in oral epithelial dysplasia and oral squamous cell carcinoma-an image analysis study.

Authors:  Megha Jain; Sowmya Kasetty; U S Sudheendra; Manisha Tijare; Samar Khan; Ami Desai
Journal:  Patholog Res Int       Date:  2014-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.